The therapeutic potential of CETP inhibitors: a patent review. (3rd April 2018)

• Record Type: Journal Article
• Authors: Wang, Xinran; Li, Wei; Hao, Lijuan; Xie, Honglei; Hao, Chenzhou; Liu, Chunchi; Li, Wenyan; Xiong, Xuqiong; Zhao, Dongmei
• Is Part Of: Expert opinion on therapeutic patents. Volume 28:Number 4(2018)
• Page Start: 331
• Page End: 340
• Publication Date: 2018-04-03
• Subjects: Cholesteryl ester transfer protein -- cardiovascular disease -- anacetrapib -- reverse cholesterol transport; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2018.1439476
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction : Epidemiological studies have identified that high levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein-cholesterol (HDL-C) are two independent causes of cardiovascular disease (CVD). Statins, niacin and fibrate are used for the treatment of CVD. However, some defects are shown in the treatment process. Thus, there is a demand for better treatment strategies that confer preferable efficacy with fewer side effects. Cholesteryl ester transfer protein (CETP) promotes the movement of CEs from HDL to LDL and VLDL in exchange for triglycerides (TGs). Areas covered : In this review, we reviewed the development and therapeutic applications of CETP inhibitors. A comprehensive review of the patents and pharmaceutical applications between 2009 and 2017 has been highlighted. Expert opinion : Recently, CETP inhibitors have attracted considerable interest in atherosclerosis-related disease. There are four drugs (torcetrapib, anacetrapib, evacetrapib and dalcetrapib) that have been clinically evaluated in phase III clinical trials and showed promising results in raising HDL-C levels, but there were suboptimal performances in reducing the risk of cardiovascular events with all the compounds. The correlation between plasma HDL-C levels and CVD incidence needs further verification. The timeline is still long for CETP inhibitors to emerge from the treatment of CVD.